hat
Linker ki lye ak MMAE ak monoklòn antikò a se ki estab nan likid ekstrazellilè, men se pa chathepsin kadejak yon fwa antikò dwòg-konjige a te mare nan antigen nan selil kansè vize ak antre nan selil kansè a, apre yo fin ki ADC a degaje MMAE a toksik ak aktive pisan mekanis anti-mitotik la. Antibody-dwòg konjige amelyore efè antitumò antikò yo epi redwi efè negatif sistemik nan ajan ki trè potent cytotoxik.
eng
The linker linking MMAE to the monoclonal antibody is stable in extracellular fluid, but is cleaved by cathepsin once the antibody-drug-conjugate has bound to the targeted cancer cell antigen and entered the cancer cell, after which the ADC releases the toxic MMAE and activates the potent anti-mitotic mechanism. Antibody-drug conjugates enhance the antitumor effects of antibodies and reduce adverse systemic effects of highly potent cytotoxic agents.